1. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Issue 9 (September 2019) Authors: Maher, Toby M; Stowasser, Susanne; Nishioka, Yasuhiko; White, Eric S; Cottin, Vincent; Noth, Imre; Selman, Moisés; Rohr, Klaus B; Michael, Andreas; Ittrich, Carina; Diefenbach, Claudia; Jenkins, R Gisli; Corte, Tamera; Glaspole, Ian; Holmes, Mark; Troy, Lauren; Veitch, Elizabeth; Bondue, Benjamin... Journal: Lancet Issue: Volume 7:Issue 9(2019) Page Start: 771 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Issue 1 (January 2020) Authors: Richeldi, Luca; Fernández Pérez, Evans R; Costabel, Ulrich; Albera, Carlo; Lederer, David J; Flaherty, Kevin R; Ettinger, Neil; Perez, Rafael; Scholand, Mary Beth; Goldin, Jonathan; Peony Yu, Kin-Hung; Neff, Thomas; Porter, Seth; Zhong, Ming; Gorina, Eduard; Kouchakji, Elias; Raghu, Ganesh Journal: Lancet Issue: Volume 8:Issue 1(2020) Page Start: 25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗